Showing 1 - 3 results of 3 for search 'Alexander Pine', query time: 0.02s Refine Results
  1. 1
    P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

    P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL by Abu-Sayeef Mirza, Alexander Pine, Ramzi Hamouche, Yusuf Rasheed, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred Lee, Stuart Seropian

    Published 2023-08-01
    Get full text
    Article
  2. 2
    P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL

    P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL by Yusuf Rasheed, Abu-Sayeef Mirza, Alexander Pine, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred Lee, Stuart Seropian

    Published 2023-08-01
    Get full text
    Article
  3. 3
    P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRY

    P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORK... by Ayesha Butt, Rolando Garcia-Milian, George Goshua, Sean Gu, John Hwa, Hyung Chun, H Michael Belmont, Nina Kello, D. Ware Branch, Michelle Petri, Jason S. Knight, Rohan Willis, Maria Laura Bertolaccini, Doruk Erkan, Alfred Lee, Anish Sharda, Alexander Pine

    Published 2023-08-01
    Get full text
    Article

Search Tools: